Relypsa Inc (RLYP)

Sector:
HEALTH CARE
Industry:
HEALTH CARE
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
John A. Orwin
Employees:
429
100 CARDINAL WAY, REDWOOD CITY, CA 94063
650-421-9500

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Relypsa, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of polymeric medicines for patients with conditions that are overlooked and undertreated and can be addressed in the gastrointestinal tract pr...

Data derived from most recent annual or quarterly report
Market Cap 1.432 Billion Shares Outstanding44.75 Million Avg 30-day Volume 1.884 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-2.15
Price to Revenue31.4986 Debt to Equity0.0 EBITDA-33.382 Million
Price to Book Value2.6665 Operating Margin-358.9646 Enterprise Value217.946 Million
Current Ratio7.516 EPS Growth0.721 Quick Ratio6.953
1 Yr BETA 52-week High/Low 0.0 / Profit Margin-363.205
Operating Cash Flow Growth-45.7097 Altman Z-Score13.1882 Free Cash Flow to Firm -55.319 Million
View SEC Filings from RLYP instead.

View recent insider trading info

Funds Holding RLYP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RLYP BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MCGIRR DAVID W J

  • Director
No longer subject to file 2016-09-01 0

SPIEGELMAN DANIEL K

  • Director
No longer subject to file 2016-09-01 0

BALL KRISTINE M CHIEF FINANCIAL OFFICER & SVP

  • Officer
No longer subject to file 2016-09-01 0

HASTINGS PAUL J

  • Director
No longer subject to file 2016-09-01 0

BERMAN LANCE CHIEF MEDICAL OFFICER AND SVP

  • Officer
No longer subject to file 2016-09-01 0

ORWIN JOHN A PRESIDENT & CEO

  • Officer
  • Director
No longer subject to file 2016-09-01 0

TORLEY HELEN

  • Director
No longer subject to file 2016-09-01 0

GARLAND J. SCOTT SVP & CHIEF COMMERCIAL OFFICER

  • Officer
No longer subject to file 2016-09-01 0

SCHUETZ THOMAS J.

  • Director
No longer subject to file 2016-09-01 0

BUTLER JOHN P.

  • Director
No longer subject to file 2016-09-01 0

STAHL WILHELM SVP, CHIEF TECHNOLOGY OFFICER

  • Officer
No longer subject to file 2016-09-01 0

KRASNOW RONALD A. SEE REMARKS

  • Officer
No longer subject to file 2016-09-01 0

CORBETT MARY SENIOR VP, HUMAN RESOURCES

  • Officer
No longer subject to file 2016-09-01 0

HILLAN KENNETH J.

  • Director
No longer subject to file 2016-09-01 0

HARRISON STEPHEN D SVP & CHIEF SCIENTIFIC OFFICER

  • Officer
No longer subject to file 2016-09-01 0

MONTGOMERY MONTE CHIEF ACCOUNTING OFFICER

  • Officer
No longer subject to file 2016-09-01 0

DONDERO JAMES D

  • 10% Owner
128,500 2016-08-17 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP IV LLC

ISALY SAMUEL D

  • 10% Owner
No longer subject to file 2016-07-22 0

LOCKEY CLAIRE SEE REMARKS

  • Officer
10,478 2015-08-17 0

VEITINGER KLAUS R DR

  • Director
2,712 2015-05-11 0

5AM PARTNERS III, LLC

5AM VENTURES III, L.P.

5AM CO-INVESTORS III, L.P.

  • 10% Owner
No longer subject to file 2014-12-09 0

5AM PARTNERS II, LLC

5AM VENTURES II LP

5AM CO-INVESTORS II LP

  • 10% Owner
1,319,480 2014-09-16 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments